Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

20 trials with published results (15%)

Research Maturity

62 completed trials (47% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

6.8%

9 terminated out of 133 trials

Success Rate

87.3%

+0.7% vs benchmark

Late-Stage Pipeline

8%

11 trials in Phase 3/4

Results Transparency

32%

20 of 62 completed with results

Key Signals

20 with results87% success

Data Visualizations

Phase Distribution

85Total
Not Applicable (24)
Early P 1 (2)
P 1 (23)
P 2 (25)
P 3 (10)
P 4 (1)

Trial Status

Completed62
Recruiting30
Unknown14
Withdrawn10
Terminated9
Active Not Recruiting5

Trial Success Rate

87.3%

Benchmark: 86.6%

Based on 62 completed trials

Clinical Trials (133)

Showing 20 of 20 trials
NCT07285044Phase 2RecruitingPrimary

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT06998355WithdrawnPrimary

BE.Amycon Registry UZ Leuven

NCT07172243RecruitingPrimary

BE.Amycon Biobank & Data Registry UZ Leuven

NCT05250973Phase 2Active Not RecruitingPrimary

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

NCT05283993Recruiting

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

NCT07494942Not ApplicableNot Yet RecruitingPrimary

Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis

NCT07130565Recruiting

Pan-Amyloid PET/CT in Various Amyloid-Related Disease

NCT07232459Recruiting

[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis

NCT05577819Not ApplicableRecruiting

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

NCT05145816Phase 1Recruiting

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

NCT05793320Not ApplicableCompletedPrimary

Carpal Tunnel Release With Risk Factors for Amyloidosis

NCT07116473Phase 3Not Yet Recruiting

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

NCT06563895Phase 3RecruitingPrimary

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT07695701Phase 4Recruiting

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

NCT01347047CompletedPrimary

HIBA-Institutional Registry of Amyloidosis

NCT07224672Phase 2RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

NCT07081646Phase 1Recruiting

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

NCT05738005Not ApplicableRecruitingPrimary

Dietary Reporting In The Amyloidoses

NCT06414746Completed

Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia

NCT04636684Not ApplicableRecruitingPrimary

Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis

Scroll to load more

Research Network

Activity Timeline